Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037209 | 1.00 | MME (0.43) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL203100 | 1.00 | MME (0.43) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL436374 | 0.98 | MME (0.44) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL200644 | 0.98 | MME (0.44) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL27524619 | 0.98 | MME (0.44) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL6102241 | 0.94 | MME (0.41) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL6102246 | 0.94 | MME (0.41) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL7848861 | 0.93 | MME (0.39) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL5328399 | 0.89 | RAB9A (0.42) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL3418395 | 0.88 | MME (0.36) | MMERAB9ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1925 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215895-A1 | Therapeutic and carrier molecules | PEPLIN BIOLIPIDS PTY LTD (AU) | 2009-08-27 | — | — | US | claimed |
| EP-1006122-B1 | PHENETHYLAMINE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-12-03 | — | — | EP | claimed |
| EP-1718602-A4 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2007-12-12 | — | — | EP | claimed |
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | claimed |
| EP-1718602-A1 | THERAPEUTIC AND CARRIER MOLECULES | Peplin Biolipids Pty Ltd. (AU) | 2006-11-08 | — | — | EP | claimed |
| WO-2005073164-A1 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2005-08-11 | — | — | WO | claimed |
| US-6255285-B1 | GASTROINTESTINAL DISORDERS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-07-03 | — | — | US | claimed |
| EP-1006122-A1 | PHENETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-06-07 | — | — | EP | claimed |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-05-21 | — | — | US | disclosed |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2026-05-07 | — | — | US | disclosed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-04-23 | — | — | US | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12605425-B2 | TNF muteins and uses thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-04-21 | — | — | US | disclosed |
| EP-0745092-A1 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1996-12-04 | — | — | EP | disclosed |
| WO-1996000738-A1 | ENDOTHELIN ANTAGONISTS II | WARNER-LAMBERT COMPANY (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0672049-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994028014-A2 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215895-A1 | Therapeutic and carrier molecules | PHKG1, PHKG2, DGKB | MME 2952/4885RAB9A 4287/4885LTA4H 738/4885 |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | PTH1R, FGF23, PTMS | MME 971/4885RAB9A 3112/4885LTA4H 1063/4885 |
| US-12605425-B2 | TNF muteins and uses thereof | TNFRSF1A, TNF, TNFSF11 | MME 629/4885RAB9A 4693/4885LTA4H 3821/4885 |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | NONO, NGLY1, PTMS | MME 1046/4885RAB9A 2985/4885LTA4H 2777/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | MME 51/4885RAB9A 2594/4885LTA4H 1939/4885 |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | CTSL, CPA4, ACE2 | MME 159/4885RAB9A 4585/4885LTA4H 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.